An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

Phase 1 Terminated 82 enrolled Bristol-Myers Squibb

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether BMS-986299 both by itself and in combination with Nivolumab and Ipilimumab is safe and tolerable in the treatment of advanced solid tumors. In addition, the ability of study drugs to stimulate an immune response against cancer will be investigated.

Timeline

Start: 2018-04-05
Primary completion: 2022-02-14
Completion: 2022-02-14

Outcome

Outcome not reported

Stopped (Business): “business objectives have changed”

Publications

Nelson BE, O'Brien S, Sheth RA, Hong DS, Naing A, Zhang X, Xu A, Hamuro L, Suryawanshi R, McKinley D, Novosiadly RD, Piha-Paul SA. Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors. J Immunother Cancer. 2025 Jan 16;13(1):e010013. doi: 10.1136/jitc-2024-010013.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-986299	Small molecule	—	Other
Subject	Ipilimumab	Monoclonal antibody	—	—
Subject	Nivolumab	Monoclonal antibody	—	—

Indications

No indication recorded.